Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)

1. Safety Profiles of Polymyxins, Aminoglycosides, and Imipenem/Cilastatin/Relebactam (IMI/REL) in the Treatment of Gram-Negative Infections: A Literature Review

- Collings H. , et al.

2. An overview of outer membrane protein A (OmpA) as a therapeutic target for Acinetobacter baumannii infection

- Islam M.M. , et al.

3. Novel Kidney Biomarkers and Antibiotics-Induced Acute Kidney Injury: A Practical Assessment of Current and Future Applications

- Karimzadeh I. , et al.

4. Study progress of novel biomarkers for early prediction of polymyxin-associated acute kidney injury

- Yang G. , et al.

5. Microbiologic cure with a simplified dosage of intravenous colistin in adults: A retrospective cohort study

- Al-Zubairy S.A. , et al.

6. Enhanced antibacterial effect of a novel Friunavirus phage vWU2001 in combination with colistin against carbapenem-resistant Acinetobacter baumannii

- Wintachai P. , et al.

7. The potential role of adjunctive ascorbic acid in the prevention of colistin-induced nephrotoxicity in critically ill patients: A retrospective study

- Al Sulaiman K. , et al.

8. The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection

- Wang Y. , et al.

9. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis

- Huang C. , et al.

10. Serum and urinary biomarkers for early detection of acute kidney injury following Hypnale spp. envenoming

- Wijewickrama E.S. , et al.

11. Dose Optimization of Colistin: A Systematic Review

- Haseeb A. , et al.

12. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins

- Wagenlehner F. , et al.

13. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis

- Liu J. , et al.

14. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)

- Truong C.B. , et al.

15. Efficacy and safety of colistin loading dose: A meta-analysis

- Bellos I. , et al.

16. Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes

- Thammathiwat T. , et al.

17. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): An investigator-driven, open-label, randomized, noninferiority controlled trial

- Cisneros J.M. , et al.

18. Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing enterobacteriaceae

- Rodríguez-Baño J. , et al.